Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

Stewart Harris; Gy?z? Kocsis; Rudolf Prager; Terry Ridge; Keval Chandarana; Natalie Halladin; Serge Jabbour

首页> 外文期刊>Canadian journal of diabetes >Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

【24h】

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

机译：胰岛素Degludec / Liraglutide（IDEGLIRA）的安全性和疗效（IDEGLIRA）每周（1W）与T2D患者对口腔抗糖尿病药物不受控制的每周（2W）的两次（2W）：双VI研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Canadian journal of diabetes》 |2017年第speca期|共1页
作者
Stewart Harris; Gy?z? Kocsis; Rudolf Prager; Terry Ridge; Keval Chandarana; Natalie Halladin; Serge Jabbour;
展开▼
作者单位

London ON;

London ON;

London ON;

London ON;

London ON;

London ON;

London ON;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献

1. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study [J] . Stewart Harris, Gy?z? Kocsis, Rudolf Prager, Canadian journal of diabetes . 2017,第Speca期

机译：胰岛素Degludec / Liraglutide（IDEGLIRA）的安全性和疗效（IDEGLIRA）每周（1W）与T2D患者对口腔抗糖尿病药物不受控制的每周（2W）的两次（2W）：双VI研究
2. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program [J] . Kamlesh Khunti, Viswanathan Mohan, Sunil M. Jain, Diabetes therapy . 2017,第3期

机译：IDegLira对印度2型糖尿病参与者口服抗糖尿病药和基础胰岛素无法控制的疗效和安全性：来自DUAL临床试验计划的数据
3. Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐na?ve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial [J] . Kaku Kohei, Araki Eiichi, Tanizawa Yukio, Diabetes, obesity & metabolism . 2019,第12期

机译：与胰岛素Degludec和Liragludec和Liraglutide在胰岛素-Na've的胰岛素Degludec和Liraglutide中的胰岛素-Na've日本患者的胰岛素Degludec和Liraglutide的卓越疗效卓越的疗效与第3型糖尿病患者，开放标签，随机试验
4. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial [O] . Stewart B. Harris, Győző Kocsis, Rudolf Prager, -1

机译：IDegLira的安全性和有效性在口服抗糖尿病药未控制的2型糖尿病患者中每周一次滴定每周两次滴定：DUAL VI随机临床试验
5. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications [O] . Carol H. Wysham, Carlos Campos, Davida Kruger 2018

机译：胰岛素Degludec / Liraglutide（IDEGLIRA）和胰岛素甲基U100 / Lixisenatide（Iglarllixi），两种新的基础胰岛素和胰高血糖素肽-1受体激动剂的安全性和有效性，在口腔上没有充分控制的糖尿病患者的基础胰岛素和胰高血糖素肽-1受体激动剂抗糖尿病药物

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study

著录项

相似文献

相关主题

期刊订阅